J. Kenney

Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.

M. Reiss, J. Lacy, M. Guinness, 2000, Cancer research.

Advances in Brief Bcl-2 Antisense Oligodeoxynucleotide Therapy of Epstein-Barr Virus-associated Lymphoproliferative Disease in Severe Combined Immunodeficient Mice 1

M. Reiss, J. Lacy, M. Guinness, 2000 .

Antisense to the Epstein‐Barr virus (EBV)‐encoded latent membrane protein 1 (LMP‐1) sensitizes EBV‐immortalized B cells to transforming growth factor‐beta and chemotherapeutic agents

M. Reiss, J. Lacy, M. Guinness, 2001, International journal of cancer.

Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells.

J. Lacy, T. Curiel, M. Guinness, 1998, Blood.

Increased soluble interleukin-1 type II receptor concentrations in postoperative patients and in patients with sepsis syndrome.

M. Cuesta, L. Moldawer, H. Oldenburg, 1996, Blood.